Our research pipeline is designed to develop treatments for genetically defined subpopulations of patients suffering from dry AMD and linked diseases. This could provide patients with access to targeted first-in-class medicines for patients with limited therapeutic options.
Pipeline
Ocular Disease Platform
Age-Related Macular Degeneration
Target
Research
Preclinical
Clinical
CLARITY 1
CLARITY 2
Precision Medicine Pipeline
Age-Related Macular Degeneration
Target
Research
Preclinical
Clinical
GEM103
Complement Factor I
GEM104
Ocular Disease
Target
Research
Preclinical
Clinical
HTRA1
Systemic Renal
Target
Modality
Research
Preclinical
Clinical